Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
210 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Wu Y, Zhu L, Chen J, Liu J, Yin K, Yang X. · J Neurol · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy and safety of aducanumab, lecanemab, and donanemab in Alzheimer's disease: A meta-analysis of randomized controlled trials.
Ali M, Shabbir H, Shaharyar M, Mukesh S, Rodriguez A, Afshani M, Kalra D, Koriesh A. · J Alzheimers Dis · 2026 · cited 0 timesmeta-analysis, review
- Efficacy and safety of lecanemab monoclonal antibody in the treatment of mild to moderate Alzheimer’s disease: a systematic review and meta-analysis
Li S, Zhang J, Huang L, Wu H, Ye Y, Liu A, Chen J, Lai S. · Front Pharmacol · cited 0 timesOpen accesssystematic-review, review
- Pharmacological and Clinical Heterogeneity of Anti-Amyloid Monoclonal Antibodies in Early Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Trials.
Vamanu A, Mastaleru A, Schreiner TG, Popescu G, Roceanu AM, Cucu AI, Patrascu A, Vulpoi GA, Bilcu RV, Cozma RS, Olariu R, Bistriceanu CE, Covali R, Cuciureanu DI, Ciubotaru A. · Med Sci (Basel) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Efficacy and safety of lecanemab monoclonal antibody in the treatment of mild to moderate Alzheimer's disease: a systematic review and meta-analysis.
Li SY, Zhang JX, Huang LZ, Wu HB, Ye YB, Liu A, Chen J, Lai S. · Front Pharmacol · 2026 · cited 0 timessystematic review
- Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis.
Shim GH, Lau ECY, Huynh ALH, Lu CY, Tan ECK. · Ageing Res Rev · 2026 · cited 7 timesmeta-analysis, systematic review
- Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, De Santis C, Gonzalez-Lorenzo M, Vignatelli L, Filippini G, Richard E. · Cochrane Database Syst Rev · 2026 · cited 53 timesOpen accessmeta-analysis, systematic review
- Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.
Perry R, Kipps C, Soto Martín ME, Bozzali M, Logroscino G, Trafford S, Dhadda S, Kanekiyo M, Goodwin A, Hodgkinson M, Hersch S, Irizarry M, Kramer L, Froelich L. · J Prev Alzheimers Dis · 2026 · cited 4 timesOpen accessclinical trial, phase iii, multicenter study
- Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model.
Bhagunde P, Penner N, Willis BA, Bell R, Charil A, Irizarry MC, Hersch S, Reyderman L. · CPT Pharmacometrics Syst Pharmacol · 2026 · cited 4 timesOpen accessclinical trial, phase iii, clinical trial, phase ii
- Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence.
Qi L, Zheng F, Tu M, Abdullah R, Zhao Y, Su X, Zhou D, Peng G. · J Prev Alzheimers Dis · 2026 · cited 5 timesOpen accessmeta-analysis, systematic review
- Predicting cognitive function in Alzheimer's clinical trials via amyloid β-protein biomarkers.
Sui Z, Feng A, Gong Y, Zha S, Lv Y, Zheng Q, Li L, Wang Y. · Br J Clin Pharmacol · 2026 · cited 1 timesmeta-analysis
- Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials.
Sharma A, Suresh V, Kola PR, Raj R, Javairia F, Nithyanandam A, Kaur A, Arora H, Uwishema O, Gorty D, Beriwal N, Verma A, Qidwai K, Singh Malhotra H, Kumar Garg R. · J Alzheimers Dis · 2026 · cited 1 timesresearch support, non-u.s. gov't, systematic review
- Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study.
van Dyck CH, Sperling R, Johnson K, Dhadda S, Kanekiyo M, Li D, Gee M, Hersch S, Irizarry M, Kramer L. · Alzheimers Dement · 2025 · cited 45 timesOpen accessrandomized controlled trial
- Regulatory, clinical, and post-marketing challenges of lecanemab for Alzheimer's disease: insights from real-world data.
Marano G, Da Cas R, Ippoliti I, Caffarra P, Locuratolo N, Vanacore N, Ancidoni A. · Neurol Sci · 2026 · cited 2 timesOpen accesssystematic review
- A randomized, placebo-controlled, double blind Phase 1 trial of the Aβ vaccine, AV-1959R, in non-cognitively impaired participants: prelude for secondary preventive therapy in preclinical AD.
Hovakimyan A, Madoyan H, Najarzadeh Z, Chilingaryan G, Petrushina I, Mamikonyan G, Lebedeva E, Zaitsev A, Mansour K, O'Malley TP, Gonen S, Kniazev R, Petrovsky N, Grinberg A, Alexander RC, Schneider LS, Ataullakhanov R, Glabe C, Ghochikyan A, Agadjanyan MG. · Mol Neurodegener · 2026 · cited 0 timesOpen accessclinical trial, phase i, randomized controlled trial
- Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid-beta drugs in Alzheimer's disease: a Bayesian meta-analysis.
Ren S, Singh J, Gsteiger S, Cogley C, Reed B, Abrams KR, Dawoud D, Owen RK, Tappenden P, Quinn TJ, Bujkiewicz S. · J Comp Eff Res · 2026 · cited 4 timesOpen accessmeta-analysis
- Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial.
Lovró Z, Sandberg A, Zetterberg H, Pierrou S, Parkkola R, Sjögren N, Scheinin M, Rinne JO. · Alzheimers Res Ther · 2026 · cited 1 timesOpen accessclinical trial, phase i, randomized controlled trial
- Comparative efficacy and safety of symptomatic therapy and disease-modifying therapy for Alzheimer's disease: a systematic review and network meta-analysis.
Liu S, Zhao M, Liu Y, Yang X, Yan H, Xu H, Wu Y, Xu Y. · Front Neurosci · 2025 · cited 7 timesOpen accesssystematic review, systematic-review
- Gantenerumab for Early Alzheimer's Disease: An Updated Systematic Review and Meta-Analysis.
Javed MN, Khan SM, Mustafa S, Mujtaba A, Amin H, Azhar N, Hameed A, Zayed A, Khalid M, Hussain JM. · Brain Behav · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis.
Arroyo-Pacheco N, Sarmiento-Blanco S, Vergara-Cadavid G, Castro-Leones M, Contreras-Puentes N. · Ageing Res Rev · 2025 · cited 28 timesmeta-analysis, systematic review
- Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease.
Chen C, Katayama S, Lee JH, Lee JY, Nakagawa M, Torii K, Ogawa T, Dash A, Irizarry M, Dhadda S, Kanekiyo M, Hersch S, Iwatsubo T. · J Prev Alzheimers Dis · 2025 · cited 26 timesOpen accessclinical trial, phase iii, multicenter study
- Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.
Hey JA, Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada M, Doraiswamy PM, Elahi FM, Rissman RA, Liang E, Flint S, Hristova E, Kesslak P, McLaine R, Albayrak A, Schaefer JF, Yu JY, Tolar L, Tolar M. · Drugs · 2026 · cited 0 timesOpen accessclinical trial, phase iii, clinical trial, phase ii
- Can IVIG Intervene in AD? Insights from Animal Experiments and Clinical Trials-A Systematic Review and Synthesis Without Meta-Analysis.
Zhao H, Zhang Z, Wang C, Lin F, Cao H. · Int J Mol Sci · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials.
Su CH, Chang YT, Tseng HS, Kuo CY, Chen JH, Chien PY, Chang YJ, Hung CC. · Clin Med (Lond) · 2025 · cited 4 timesOpen accesssystematic review, review-article
- Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review.
Jiang X, Lv G, Xiong X, Yuan J, Kevin Lu Z. · J Alzheimers Dis · 2026 · cited 0 timesresearch support, non-u.s. gov't, systematic review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.